Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 175

Sort by

Sort Order Select

Journal Articles

Lymphoma Diagnosis and Classification Using Next Generation Sequencing of 30 CD Markers and Machine Learning As an Alternative to Immunohistochemistry

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, Jeffrey Justin Estella, Lori A. Leslie, Tatyana Feldman, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2023-187534

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster

Blood (2023) 142 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2023-190201

Published: 2023

Journal Articles

Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia

Tatyana Feldman, Alexandra Della Pia, Geeny Lee, Thomas S. Gunning, Michael Pelliccia, Tony Varughese, Harsh Parmar, Andrew Ip, Lori A. Leslie, Andre Goy, Samuel Singer

Blood (2023) 142 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2023-187164

Published: 2023

Journal Articles

Polygenic HLA-Class I and HLA-Class II Models Define Various Types of Lymphoma

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, Jeffrey Justin Estella, Lori A. Leslie, Tatyana Feldman, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 6110.

https://doi.org/10.1182/blood-2023-187686

Published: 2023

Journal Articles

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2023-187606

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang

Blood (2023) 142 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2023-174681

Published: 2023

Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang

Blood (2023) 142 (Supplement 1): 106.

https://doi.org/10.1182/blood-2023-174273

Published: 2023

Journal Articles

CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights

Alaa Ali, Andre Goy, Kieron Dunleavy

Blood (2022) 140 (13): 1461–1469.

https://doi.org/10.1182/blood.2022016226

Published: 2022

Journal Articles

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Blood (2021) 137 (13): 1832–1835.

https://doi.org/10.1182/blood.2020006245

Published: 2021

Includes: Supplemental data

Journal Articles

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Blood (2019) 134 (Supplement_1): 245.

https://doi.org/10.1182/blood-2019-129624

Published: 2019

Journal Articles

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Blood (2019) 134 (Supplement_1): 5333.

https://doi.org/10.1182/blood-2019-122900

Published: 2019

Journal Articles

A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Chaitra Ujjani, MD, Anthony R. Mato, MDMSCE, Jonathon B. Cohen, MDMS, Jakub Svoboda, MD, David Andorsky, MD, Andre Goy, MD, Michael L. Wang, MD, Anita Kumar, MD, Peggy Ann Torney, MS, Michelle Dawson, PhD, Cynthia Elesinmogun, PharmD, Shaum M Kabadi, PhDMPH, Brian Seal, MBA, PhD, John M. Pagel, MD PhD DSc, Scott D Ramsey, MD PhD

Blood (2019) 134 (Supplement_1): 5892.

https://doi.org/10.1182/blood-2019-122845

Published: 2019

Journal Articles

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sudarsan Kollimuttathuliam, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 4576.

https://doi.org/10.1182/blood-2019-132052

Published: 2019

Journal Articles

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Blood (2019) 134 (Supplement_1): 4311.

https://doi.org/10.1182/blood-2019-130062

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Blood (2019) 134 (Supplement_1): 763.

https://doi.org/10.1182/blood-2019-129097

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Blood (2019) 134 (Supplement_1): 1583.

https://doi.org/10.1182/blood-2019-131168

Published: 2019

Journal Articles

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Simon Rule, Martin H. Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MRCP, FRPath, PhD, Brad S. Kahl, MD, Jose Angel Hernandez-Rivas, MD PhD, Keqin Qi, PhD, Sanjay Deshpande, Lori Parisi, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 1538.

https://doi.org/10.1182/blood-2019-124691

Published: 2019

NARROW

Lymphoma Diagnosis and Classification Using Next Generation Sequencing of 30 CD Markers and Machine Learning As an Alternative to Immunohistochemistry

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia

Polygenic HLA-Class I and HLA-Class II Models Define Various Types of Lymphoma

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only